BioNTech RNA Pharmaceuticals GmbH , 55131 Mainz , Germany.
TRON gGmbH , 55131 Mainz , Germany.
Mol Pharm. 2018 Sep 4;15(9):3909-3919. doi: 10.1021/acs.molpharmaceut.8b00370. Epub 2018 Aug 9.
Targeting mRNA to eukaryotic cells is an emerging technology for basic research and provides broad applications in cancer immunotherapy, vaccine development, protein replacement, and in vivo genome editing. Although a plethora of nanoparticles for efficient mRNA delivery exists, in vivo mRNA targeting to specific organs, tissue compartments, and cells remains a major challenge. For this reason, methods for reporting the in vivo targeting specificity of different mRNA nanoparticle formats will be crucial. Here, we describe a straightforward method for monitoring the in vivo targeting efficiency of mRNA-loaded nanoparticles in mice. To achieve accurate mRNA delivery readouts, we loaded lipoplex nanoparticles with Cre-recombinase-encoding mRNA and injected these into commonly used Cre reporter mouse strains. Our results show that this approach provides readouts that accurately report the targeting efficacy of mRNA into organs, tissue structures, and single cells as a function of the used mRNA delivery system. The method described here establishes a versatile basis for determining in vivo mRNA targeting profiles and can be systematically applied for testing and improving mRNA packaging formats.
靶向真核细胞的 mRNA 是一种新兴的基础研究技术,在癌症免疫治疗、疫苗开发、蛋白质替代和体内基因组编辑方面提供了广泛的应用。尽管有大量的纳米颗粒可用于高效传递 mRNA,但将 mRNA 靶向特定器官、组织隔室和细胞仍然是一个主要挑战。因此,报告不同 mRNA 纳米颗粒形式的体内靶向特异性的方法将是至关重要的。在这里,我们描述了一种在小鼠中监测负载 mRNA 的纳米颗粒体内靶向效率的简单方法。为了实现准确的 mRNA 传递读出,我们将 Cre 重组酶编码 mRNA 加载到脂质体纳米颗粒中,并将其注射到常用的 Cre 报告小鼠品系中。我们的结果表明,这种方法提供的读出结果准确地报告了 mRNA 作为所用 mRNA 传递系统的功能靶向到器官、组织结构和单个细胞的效率。这里描述的方法为确定体内 mRNA 靶向谱奠定了通用基础,并可系统地用于测试和改进 mRNA 包装形式。